About: Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease
Creator	Temperton, Nigel Ball, Jonathan Tsoleridis, Theocharis Chappell, Joseph Mcclure, C Tarr, Alexander Urbanowicz, Richard Brooks, Tim Carlile, Matthew Clark, Gemma Fairclough, C Gomez, Nancy Holmes, Nadine Hrushikesh, Divyateja Irving, William Loose, Matthew Moore, Christopher Sang, Fei Thomson, Brian Tighe, Patrick
source	MedRxiv
abstract	COVID-19 continues to cause a pandemic, having infected more than 20 million people globally. Successful elimination of the SARS-CoV-2 virus will require an effective vaccine. However, the immune correlates of infection are currently poorly understood. While neutralizing antibodies are believed to be essential for protection against infection, the contribution of the neutralizing antibody response to resolution of SARS-CoV-2 infection has not yet been defined. In this study the antibody responses to the SARS-CoV-2 spike protein and nucleocapsid proteins were investigated in a UK patient cohort, using optimised immunoassays and a retrovirus-based pseudotype entry assay. It was discovered that in severe COVID-19 infections an early antibody response to both antigens was associated with improved prognosis of infection. While not all SARS-CoV-2-reactive sera were found to possess neutralizing antibodies, neutralizing potency of sera was found to be greater in patients who went on to resolve infection, compared with those that died from COVID-19. Furthermore, viral genetic variation in spike protein was found to influence the production of neutralizing antibodies. Infection with the recently described spike protein variant 614G produced higher levels of neutralizing antibodies when compared to viruses possessing the 614D variant. These findings support the assertion that vaccines targeting generation of neutralizing antibodies may be useful at limiting SARS-CoV-2 infection. Assessment of the antibody responses to SARS-CoV-2 at time of diagnosis will be a useful addition to the diagnostic toolkit, enabling stratification of clinical intervention for severe COVID-19 disease.
has issue date	2020-08-24(xsd:dateTime)
bibo:doi	10.1101/2020.08.22.20176834
has license	medrxiv
sha1sum (hex)	f7133efab88c5c955a6d73604e5c2a29cbc879ad
schema:url	https://doi.org/10.1101/2020.08.22.20176834
resource representing a document's title	Potent anti-SARS-CoV-2 Antibody Responses are Associated with Better Prognosis in Hospital Inpatient COVID-19 Disease
resource representing a document's body	covid:f7133efab88c5c955a6d73604e5c2a29cbc879ad#body_text
is schema:about of	named entity 'infection' named entity 'infections' named entity 'Disease' named entity 'COVID-19' named entity 'COHORT' named entity 'CLINICAL INTERVENTION' named entity 'MORE THAN' named entity 'ASSAY' named entity 'PATIENT' named entity 'NUCLEOCAPSID PROTEINS' named entity 'POORLY' named entity 'RESPONSES' named entity 'DIAGNOSTIC' named entity 'THESE' named entity 'INFLUENCE' named entity 'STRATIFICATION' named entity 'COMPARED' named entity 'MAY BE' named entity 'VIRUSES' named entity 'PATIENTS' named entity 'NEUTRALIZING ANTIBODIES' named entity 'levels' named entity 'COVID-19' named entity 'improved' named entity 'enabling' named entity 'neutralizing antibody' named entity 'COVID-19' named entity 'pandemic' named entity 'reactive' named entity 'compared' named entity 'SARS-CoV-2' named entity 'produced' named entity 'Infection' named entity 'Inpatient' named entity 'neutralizing antibodies' named entity 'spike protein' named entity 'neutralizing antibodies' named entity 'Infection' named entity 'spike protein' named entity 'retrovirus' named entity 'COVID-19' named entity 'clinical intervention' named entity 'COVID-19 disease' named entity 'pseudotype' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'nucleocapsid' named entity 'polymorphic' named entity 'glycine' named entity 'Research Ethics' named entity 'clinical assays' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'long-term' named entity 'antibodies' named entity 'Promega' named entity 'SARS-CoV-2' named entity 'infection' named entity 'nucleocapsid' named entity 'antiviral' named entity 'peer review' named entity 'Gag-Pol' named entity 'infection' named entity 'antibodies' named entity 'prognosis' named entity 'COVID-19 disease'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software